HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Progabide for refractory partial epilepsy: a controlled add-on trial.

Abstract
Progabide, an experimental GABA-ergic antiepileptic drug, was given in a placebo-controlled double-blind cross-over trial to 19 adult patients with chronic partial epilepsy refractory to previous high-dose antiepileptic drug therapy. A mean daily dose of 32 mg/kg (range, 16 to 63) of progabide did not significantly change the seizure frequency. In patients with a therapeutic response, progabide led to an increase in the plasma concentration of phenytoin and phenobarbital. Comedication with carbamazepine was associated with a poor response to progabide. Side effects were mild except for a several-fold increase of SGOT and SGPT, which required withdrawal of progabide in one patient. Progabide does not seem to be the drug urgently needed for failures of previous high-dose drug therapy.
AuthorsD Schmidt, K Utech
JournalNeurology (Neurology) Vol. 36 Issue 2 Pg. 217-21 (Feb 1986) ISSN: 0028-3878 [Print] United States
PMID3511402 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Anticonvulsants
  • Carbamazepine
  • progabide
  • gamma-Aminobutyric Acid
  • Phenytoin
  • Phenobarbital
Topics
  • Adolescent
  • Adult
  • Aged
  • Anticonvulsants
  • Carbamazepine (blood, metabolism)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Interactions
  • Drug Therapy, Combination
  • Epilepsy (drug therapy)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Phenobarbital (blood, metabolism)
  • Phenytoin (blood, metabolism)
  • Random Allocation
  • gamma-Aminobutyric Acid (adverse effects, analogs & derivatives, metabolism, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: